Clinical Trials Logo

Crow's Feet clinical trials

View clinical trials related to Crow's Feet.

Filter by:

NCT ID: NCT06021418 Active, not recruiting - Crow's Feet Clinical Trials

Efficacy and Safety of DKB-119 in Patients in Crow's Feet

Start date: November 2, 2020
Phase: N/A
Study type: Interventional

To prove the non-inferiority of DKB-119 by evaluating the injecting efficacy and safety DKB-119 and control for patients in crow's feet

NCT ID: NCT04985916 Active, not recruiting - Crow's Feet Clinical Trials

ET-01 in Subjects With Lateral Canthal Lines, LCL-210

Start date: July 19, 2021
Phase: Phase 2
Study type: Interventional

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

NCT ID: NCT04818203 Recruiting - Crow's Feet Clinical Trials

A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Cluster of Autologous Dermal Fibroblast on Bilateral Crow's Feet

Start date: July 20, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study is a phase 1/2 clinical trial to evaluate the safety and efficacy of administering clusters of autologous dermal fibroblasts to subjects with periorbital wrinkles on both sides. If subjects who have signed the Informed consent form voluntarily are enrolled in this study, they will be tested for eligibility during the screening period. Subjects will visit the study site a total of 6 times while participating in this study. The subjects who meet the inclusion/exclusion criteria will receive a total of one dose of the IP (Visit 3). Then, the efficacy evaluation will be conducted at Visit 4 (Week 2), Visit 5 (Week 12), and Visit 6 (Week 24), and safety will also be evaluated at each visit.

NCT ID: NCT03912805 Completed - Crow's Feet Clinical Trials

ET-01 in Subjects With Lateral Canthal Lines, LCL-209

Start date: February 27, 2019
Phase: Phase 2
Study type: Interventional

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

NCT ID: NCT03839693 Completed - Clinical trials for Lateral Canthal Lines

ET-01 in Subjects With Lateral Canthal Lines, LCL-208

Start date: October 16, 2018
Phase: Phase 2
Study type: Interventional

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

NCT ID: NCT03655691 Completed - Clinical trials for Lateral Canthal Lines

ET-01 in Subjects With Lateral Canthal Lines, LCL-207

Start date: August 16, 2018
Phase: Phase 2
Study type: Interventional

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

NCT ID: NCT03326856 Completed - Clinical trials for Lateral Canthal Lines

ET-01 in Subjects With Lateral Canthal Lines

Start date: October 25, 2017
Phase: Phase 2
Study type: Interventional

This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).

NCT ID: NCT01951742 Completed - Clinical trials for Lateral Canthal Lines

Dose Finding Study In Subjects With Crow's Feet

Start date: September 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to establish the therapeutic range of ANT-1401 in the treatment of Crow's Feet.

NCT ID: NCT01358695 Completed - Clinical trials for Lateral Canthal Lines

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.

NCT ID: NCT01124565 Completed - Facial Wrinkles Clinical Trials

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Start date: May 2010
Phase: Phase 2
Study type: Interventional

This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.